Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled trial of fevipiprant in uncontrolled severe asthma
jRCT2080223052Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Fevipiprant arm with Placebo arm (2 arms). Started Dec 2015; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2080223052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223052.